Navigation Links
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Date:2/5/2010

LONDON and PALO ALTO, Calif., Feb. 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth, Ph.D., chief executive officer, will deliver a corporate overview and business update at the 12th Annual BIO CEO & Investor Conference.  The conference will be held February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City.

Silence's presentation will take place at 11:00 a.m. Eastern on Monday, February 8, 2010.  The corporate update provided by Dr. Haworth will include an overview of the company's recent merger with Intradigm Corporation, as well as details on the company's expanded RNA interference (RNAi) therapeutic platform and pipeline.  

To access a live audio webcast of the presentation, please log on through a link located on the Presentations page of the Investor Relations section of Silence's website at http://www.silence-therapeutics.com/index.php?option=com_content&task=view&id=88&Itemid=88

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated
'/>"/>

SOURCE Silence Therapeutics PLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
3. Silence Therapeutics Patent Update
4. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
5. Organizational Changes at Silence Therapeutics
6. Silence Therapeutics Announces Successful Opposition of Glover Patent
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
10. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
11. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... Jan. 12 The Risk Management and Patient,Safety ... 2009 audio,program calendar. The RM&PSI ( http://www.rmpsi.com ... ), is a national leader in,clinical risk management ... health care institutions. , ...
... The French agency Agence de Medecine,Preventive (AMP) announced ... Director for the SIVAC (Supporting Independent Immunization and,Vaccine ... to,the development of national immunization technical advisory groups ... in Asia. These committees will help,national health authorities ...
... PARK, Ill., Jan. 12 Abbott today is,announcing ... previously issued 2008 earnings-per-share guidance of $3.31 to ... expects earnings per share,of $3.65 to $3.70 under ... basis. The midpoint of this 2009 guidance ...
Cached Biology Technology:The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 2The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 3French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Abbott Announces Earnings Guidance for 2009 2
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... pregnant women have twice the risk of preterm delivery ... to a new study by the Kaiser Permanente Division ... Oxford University Press,s journal Human Reproduction on ... Embryology. The study found that pregnant women with ...
... RIVERSIDE, Calif. The leading cause of death in all ... to chemotherapy, a form of treatment in which chemicals are ... UC Riverside biochemists that focuses on cancer cells reports that ... vegetables and fruit improves cancer cells, response to chemotherapy. ...
... The Marine Mammal Center is seeing a large number of ... a study to determine when and why the sea lions contract ... a surge in the number of sea lions admitted as a ... be lethal for patients. The current research will focus on ...
Cached Biology News:Depression during pregnancy can double risk of preterm delivery 2How eating fruit and vegetables can improve cancer patients' response to chemotherapy 2The Marine Mammal Center begins new leptospirosis study in California 2
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. Thousands ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive DNA/RNA ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... a synthetic peptide whose sequence is from the C-terminal end of the ... extends from amino acids 429 to 448 of RAR*. The sequence ... - V - S - P - S - S - V ... - Q - S - P - L - L - Q ...
... is the next step in the evolution ... track system that delivers labware to multiple ... 10 times the throughput of ordinary microplate ... a variety of configurations to meet any ...
Biology Products: